CoChat

HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target

Ahcene Djaballah, Selma, Daniel, Francesca, Milani, Anna, Ricagno, Gianmarco, Lonardi, Sara · 2022 · American Society of Clinical Oncology Educational Book

The DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.

Abstract

Human epidermal growth factor receptor 2 ( HER2) is a well-known oncogenic driver in different tumors and an approved therapeutic target in breast and gastroesophageal cancer. In metastatic colorectal cancer, only 3% to 5% of patients present with HER2 alterations: somatic mutations and amplifications. HER2 was first assessed as a biomarker of resistance to anti- EGFR therapy; however, in more recent years, its role as a potential actionable target has emerged. In this article, we discuss the predictive and prognostic value of HER2 in metastatic colorectal cancer, its emerging role as an actionable therapeutic target, and its possible future developments.

Overview

Integrity signals

Registry

Crossref · 10.1200/edbk_351354

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 75 references

Research works printed but not linked: 10

  1. Laurent-Puig P, 2016, Ann Oncol, 27, Vi151
  2. Edenfield WJ, 2014, J Clin Oncol, 32
  3. Strickler JH, 2021, J Clin Oncol, 39
  4. Cavanna L, 2018, Oncol Lett, 15, 5787
  5. Clark JW, 2003, Onkologie, 26, 13
  6. Messersmith WA, 2019, J Natl Compr Cancer Netw, 17, 599
  7. Yoshino T, 2021, J Clin Oncol, 39
  8. Raghav KPS, 2021, J Clin Oncol, 39
  9. Li W, 2022, J Clin Oncol, 40
  10. Siena S, 2016, J Clin Oncol, 34

Cited by

See all 119

Metadata

Authors
Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S.
Affiliations
  • Medical Oncology Unit 3, Veneto Institute of Oncology IRCCS, Padua, Italy
  • Istituto Oncologico Veneto (IT)
  • University of Padua (IT)
Venue
American Society of Clinical Oncology Educational Book
Published
2022-07
Volume
42
Issue
42
Pages
219-232
ISSN
  • 1548-8748 (ISSN-L)
  • 1548-8756
OpenAlex
W4280492853
Cited by
95
References
75
Citations by year
2026: 9 · 2025: 28 · 2024: 34 · 2023: 17 · 2022: 7
FWCI
8.99
Type
journal article
Language
en
Open access
closed
Locations
  • American Society of Clinical Oncology Educational Book (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
HER2, metastatic colorectal cancer, HER2 mutation, HER2 amplification, predictive biomarkers, prognostic factors, anti-EGFR therapy resistance, targeted therapy, therapeutic target
MeSH terms
Humans, Prognosis, Colorectal Neoplasms, Erb-b2 Receptor Tyrosine Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. https://app.cochat.ai/papers/10.1200/edbk_351354
The paper
Ahcene Djaballah, S., Daniel, F., Milani, A., Ricagno, G., & Lonardi, S. (2022). HER2 in Colorectal Cancer: The Long and Winding Road From Negative Predictive Factor to Positive Actionable Target. American Society of Clinical Oncology Educational Book. https://doi.org/10.1200/edbk_351354

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.